Black Diamond Therapeutics (BDTX) to Release Quarterly Earnings on Thursday

Black Diamond Therapeutics (NASDAQ:BDTX - Get Free Report) will likely be announcing its Q1 2025 earnings results before the market opens on Thursday, May 8th. Analysts expect Black Diamond Therapeutics to post earnings of $0.10 per share and revenue of $23.33 million for the quarter.

Black Diamond Therapeutics (NASDAQ:BDTX - Get Free Report) last released its earnings results on Thursday, March 6th. The company reported ($0.28) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.31) by $0.03. On average, analysts expect Black Diamond Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Black Diamond Therapeutics Stock Performance

Black Diamond Therapeutics stock traded down $0.12 during midday trading on Tuesday, reaching $1.56. The company's stock had a trading volume of 278,978 shares, compared to its average volume of 1,469,445. Black Diamond Therapeutics has a fifty-two week low of $1.20 and a fifty-two week high of $7.66. The firm has a market capitalization of $88.13 million, a PE ratio of -1.18 and a beta of 2.63. The stock's 50 day simple moving average is $1.62 and its 200 day simple moving average is $2.19.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on BDTX shares. Stifel Nicolaus cut their target price on shares of Black Diamond Therapeutics from $16.00 to $15.00 and set a "buy" rating for the company in a research report on Friday, March 7th. Wedbush reissued an "outperform" rating and issued a $11.00 price objective on shares of Black Diamond Therapeutics in a research report on Wednesday, March 19th. Finally, HC Wainwright raised their target price on Black Diamond Therapeutics from $11.00 to $12.00 and gave the company a "buy" rating in a report on Tuesday, March 18th. Five analysts have rated the stock with a buy rating, According to data from MarketBeat, Black Diamond Therapeutics has a consensus rating of "Buy" and an average target price of $14.60.

Insider Transactions at Black Diamond Therapeutics

In other news, major shareholder Growth N. V. Biotech sold 5,784,292 shares of Black Diamond Therapeutics stock in a transaction that occurred on Wednesday, March 19th. The stock was sold at an average price of $2.07, for a total value of $11,973,484.44. Following the completion of the transaction, the insider now owns 2,733,547 shares in the company, valued at approximately $5,658,442.29. This trade represents a 67.91 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 8.87% of the company's stock.

About Black Diamond Therapeutics

Black Diamond Therapeutics, Inc, a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma.